Safety of Buspirone and Doxepin During Pregnancy
Neither buspirone nor doxepin should be considered first-line safe options during pregnancy, but buspirone has more reassuring preliminary data while doxepin carries greater concerns for neonatal effects and should be avoided if possible.
Buspirone (Buspar) in Pregnancy
FDA Classification and Animal Data
Buspirone is classified as FDA Pregnancy Category B, meaning animal reproduction studies showed no fetal damage at doses approximately 30 times the maximum recommended human dose in rats and rabbits 1. However, the critical caveat is that adequate and well-controlled studies in pregnant humans have not been performed 1.
Human Pregnancy Data
The most relevant evidence comes from a 2022 prospective registry study that provides the only rigorously ascertained human data on first-trimester buspirone exposure 2. Among 68 evaluable women (72 infants including twins) exposed to buspirone during the first trimester, zero major malformations were observed 2. While this sample size is small, the prospective methodology and rigorous outcome ascertainment make this the highest quality human evidence available.
Clinical Recommendation for Buspirone
Buspirone should only be used during pregnancy if clearly needed and the maternal benefit justifies the unknown fetal risk 1. The decision framework should prioritize:
- Whether safer alternatives exist for the specific anxiety disorder
- Severity of maternal anxiety and impact on maternal-fetal wellbeing
- Risk of untreated maternal psychiatric illness
Doxepin in Pregnancy
FDA Classification and Concerns
Doxepin's pregnancy safety profile is considerably more problematic. While animal studies showed no evidence of harm 3, there is a documented case report of apnea and drowsiness in a nursing infant whose mother was taking doxepin 3. This raises significant concerns about neonatal effects.
Tricyclic Antidepressant Class Considerations
As a tricyclic antidepressant, doxepin belongs to a class with known concerns during pregnancy. The FDA label explicitly states that safety in pregnancy has not been established despite animal data 3.
Neonatal Withdrawal and Toxicity
A 1999 case report documented a 9-day-old infant who developed poor sucking and swallowing, muscle hypotonia, vomiting, drowsiness, and weight loss while being breastfed by a mother taking only 35 mg/day of doxepin 4. All adverse effects resolved within 48 hours of stopping breastfeeding 4. This demonstrates that even low doses can accumulate in newborns due to their considerably decreased metabolic activity, which may be further reduced by hyperbilirubinemia 4.
Clinical Recommendation for Doxepin
Doxepin should be avoided during pregnancy whenever possible. If a pregnant woman is already taking doxepin:
- Strongly consider switching to a better-studied antidepressant with more favorable pregnancy data
- If continuation is absolutely necessary due to treatment-resistant depression, use the lowest effective dose
- Plan for close neonatal monitoring at delivery for signs of withdrawal or toxicity
- Breastfeeding should be approached with great caution or avoided entirely 4
Critical Decision-Making Algorithm
Step 1: Assess maternal psychiatric severity
- Is the anxiety/depression causing significant functional impairment?
- Is there risk of maternal harm from untreated illness?
Step 2: Consider safer alternatives first
- For anxiety: Consider SSRIs with better pregnancy data (sertraline, escitalopram)
- For depression: Consider SSRIs or SNRIs with established safety profiles
- Non-pharmacologic interventions (CBT, supportive therapy)
Step 3: If buspirone or doxepin must be used
- Buspirone: May be considered if safer alternatives have failed and maternal benefit clearly outweighs unknown fetal risk
- Doxepin: Should only be used in severe, treatment-resistant cases where benefits clearly outweigh documented risks of neonatal effects
Step 4: Monitoring and planning
- Document shared decision-making discussion
- Use lowest effective dose
- Plan for neonatal monitoring at delivery
- Arrange pediatric follow-up for exposed infants
Common Pitfalls to Avoid
Assuming "Category B" means "safe" - Category B only means animal studies were reassuring; human data for buspirone remains limited 1, 2
Underestimating neonatal accumulation risk - Newborns have dramatically reduced drug metabolism, particularly with tricyclics like doxepin 4
Failing to plan for delivery - Infants exposed to psychotropics in utero need monitoring for withdrawal symptoms and toxicity in the immediate postnatal period
Not considering the risk of untreated maternal illness - Severe untreated anxiety or depression can negatively impact pregnancy outcomes, making treatment sometimes necessary despite medication risks